Ondansetron hydrochloride dihydrate
Code | Size | Price |
---|
TAR-T1478-1mL | 1 mL * 10 mM (in DMSO) | £95.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1478-25mg | 25mg | £103.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1478-50mg | 50mg | £107.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1478-100mg | 100mg | £117.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1478-200mg | 200mg | £125.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1478-1g | 1g | £139.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Ondansetron hydrochloride is a competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
CAS:
103639-04-9
Formula:
C18H24ClN3O3
Molecular Weight:
365.86
Pathway:
GPCR/G Protein; Neuroscience
Purity:
0.9971
SMILES:
O.O.Cl.Cc1nccn1CC1CCc2c(C1=O)c1ccccc1n2C
Target:
5-HT Receptor
References
1. Ye JH, et al. CNS Drug Rev. 2001, 7(2):199-213.
2. Weissenburger J, et al. Fundam Clin Pharmacol. 2009, 23(6):719-26.
3. Sardi I, et al. Cancer Lett. 2014, 353(2):242-7.